Juvenescence Limited, a clinical stage AI-enabled biotech company, is pleased to announce the acquisition of Ro5 Inc., a proprietary AI drug discovery company. This acquisition enhances Juvenescence’s artificial intelligence/machine learning drug discovery capabilities and forms a central component of its strategic partnership with Abu Dhabi-based global healthcare company M42, announced in April 2025.
Ro5’s platform leverages a proprietary Biomedical Knowledge Graph, comprising over 85 million nodes and approximately 400 million relationships, to uncover novel associations in biological processes and enable a robust evaluation of drug targets based on biological, therapeutic, and market potential. The Company’s AI Chemistry Platform incorporates state-of-the art machine learning models and cheminformatics tools, facilitating rapid and efficient discovery and design of novel compounds from hit identification through to lead optimisation.
The acquisition of Ro5 follows Juvenescence’s recent announcement of a $76 million first-close of its Series B-1 financing round led by cornerstone investor M42, with follow-on investments from existing investors. The second close of the Series B-1 is anticipated in the third quarter of 2025. Proceeds will support clinical milestones and AI-driven development across Juvenescence’s portfolio of therapeutics targeting age-related diseases.
The integration of Ro5’s AI drug discovery platform and expert team into Juvenescence will accelerate the identification and development of AI-enabled therapeutics, reinforcing the company’s growing pipeline in cognition, cardio-metabolism, immunity, and cellular repair.
Dr Richard Marshall CBE, CEO of Juvenescence, said: “We are delighted to welcome the Ro5 team and the Company’s capabilities into Juvenescence. The addition of Ro5’s AI platform significantly enhances our drug discovery capabilities, accelerating our efforts to identify and advance effective therapeutics to extend healthspan. This acquisition is also a critical part of our wider strategy with M42 to deliver a pipeline of transformative therapies and establish a world-class life sciences hub in Abu Dhabi. Together, we remain committed to improving the lives of millions of patients.”
Charles Dazler Knuff, CEO of Ro5, added: “The Ro5 team are thrilled to be joining the world class drug development team at Juvenescence. Embedding our AI-driven drug discovery capabilities into Juvenescence’s operations will accelerate their ability to advance next-generation therapeutics. Together with our partners at M42 we are also laying the foundations for a pioneering life sciences ecosystem in Abu Dhabi that leverages AI innovation to transform patient care and global health outcomes.”
